Microbial interaction between HIV-1 and anaerobic bacteria producing butyric acid: Its potential implication in AIDS progression

Future Virology

Volumn 7, Issue 10, 2012, Pages 1005-1014

  Imai, Kenichi ^a   Ochiai, Kuniyasu ^a   Okamoto, Takashi ^b  

^a NIHON UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

butyrate producing bacteria; butyric acid; HDAC; histone deacetylase; microbial interaction

Indexed keywords

ANTIRETROVIRUS AGENT; BUTYRIC ACID; CYTOKINE; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RNA POLYMERASE II; SHORT CHAIN FATTY ACID; TRANSACTIVATOR PROTEIN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANAEROBIC BACTERIUM; BACTERIAL METABOLISM; BACTERIUM CULTURE; BACTEROIDES; CHROMATIN; CLOSTRIDIUM; DEACETYLATION; ENTERITIS; FUSOBACTERIUM NUCLEATUM; GASTROINTESTINAL TRACT; GENE EXPRESSION; GENETIC TRANSCRIPTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; LATENT VIRUS INFECTION; LONG TERMINAL REPEAT; METABOLITE; MOUTH CAVITY; NONHUMAN; OPPORTUNISTIC INFECTION; ORGANISMAL INTERACTION; PERIODONTAL DISEASE; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; VAGINA; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 84867650656     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.92     Document Type: Review

References (60)

1. Hunt PW. HIV and infammation: mechanisms and consequences. Curr. HIV/AIDS Rep. 9(2), 139-147 (2012).
2. Bafca A, Scanga CA, Schito M et al. Infuence of coinfecting pathogens on HIV expression: evidence for a role of Toll-like receptors. J. Immunol. 172, 7229-7234 (2004). (Pubitemid 38747580)
3. Blanchard A, Montagnier L, Gougeon ML. Infuence of microbial infections on the progression of HIV disease. Trends Microbiol. 5, 326-331 (1997). (Pubitemid 27362296)
4. Mirmonsef P, Krass L, Landay A, Spear GT. The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Curr. HIV Res. 10(3), 202-210 (2012).
5. Jarvis GA, Chang TL. Modulation of HIV transmission by Neisseria gonorrhoeae: molecular and immunological aspects. Curr. HIV Res. 10(3), 211-217 (2012).
6. Mbopi-Keou FX, Belec L, Teo CG, Scully C, Porter SR. Synergism between HIV and other viruses in the mouth. Lancet Infect. Dis. 416-424 (2002). (Pubitemid 34693259)
7. Okamoto T, Matsuyama T, Mori S et al. Augmentation of human immunodefciency virus type 1 gene expression by tumor necrosis factor alpha. AIDS Res. Hum. Retroviruses 5, 131-138 (1989). (Pubitemid 19116042)
8. Bajaj JS, Singh A, Aggarwal SK, Chattopadhya D, Baveja UK. Synergistic immunosuppression by candida in HIV infection: a cytokine based analysis. J. Commun. Dis. 32, 1-9 (2000).
9. Saxena D, Li Y, Yang L et al. Human microbiome and HIV/AIDS. Curr. HIV/AIDS Rep. 9, 22-51(2012).
10. Louis P, Young P, Holtrop G, Flint HJ. Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene. Environ. Microbiol. 12(2), 304-314 (2010).
11. Berni R, Di Costanzo M, Leone L. The epigenetic effects of butyrate: potential therapeutic implications for clinical practice. Clin. Epigenetics. 4(1), 4 (2012).
12. Kurita-Ochiai T, Amano S, Fukushima K, Ochiai K. Cellular events involved in butyric acid-induces T cell apoptosis. J. Immunol. 171, 3576-3584 (2003) (Pubitemid 37254560)
13. Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6, 111 (2009).
14. Imai K, Ochiai K, Okamoto T. Reactivation of latent HIV-1 infection by the periodontopathic bacterium Porphyromonas gingivalis involves histone modifcation. J. Immunol. 182, 3688-3695 (2009).
15. Imai K, Yamada K, Tamura M, Ochiai K, Okamoto T. Reactivation of latent HIV-1 by a wide variety of butyric acid-producing bacteria. Cell Mol. Life Sci. 69, 2583-2592 (2012).
16. Macia L, Thorburn AN, Binge LC et al Microbial infuences on epithelial integrity and immune function as a basis for infammatory diseases. Immunol. Rev. 245, 164-176 (2012).
17. Riggs MG, Whittaker RG, Neumannn JR, Ingram VM. n-Butyrate causes histone modifcation in HeLa and Friend erythroleukaemia cells. Nature 268, 462-464 (1977).
18. Delcuve GP, Khan DH, Davie Jr. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin. Epigenetics 4(1), 5 (2012).
19. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 460, 587-591 (2009).
20. Ferrari R, Berk AJ, Kurdistani SK. Viral manipulation of the host epigenome for oncogenic transformation. Nat. Rev. Genet. 10, 290-294 (2009).
21. Santos-Rebouças CB, Pimentel MM. Implication of abnormal epigenetic patterns for human diseases. Eur. J. Hum. Genet. 15, 10-17 (2007). (Pubitemid 44921660)
22. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 128, 707-719 (2007). (Pubitemid 46273570)
23. Siliciano JD, Kajdas J, Finzi D et al. Long-term follow-up studies confrm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9, 727-728 (2003). (Pubitemid 36749221)
24. Imai K, Okamoto T: Transcriptional repression of human immunodefciency virus type 1 by AP-4. J. Biol. Chem. 281, 12495-12505 (2006). (Pubitemid 43855336)
25. Coull JJ, Romerio F, Sun JM et al. The human factors YY1 and LSF repress the human immunodefciency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J. Virol. 74, 6790-6799 (2000). (Pubitemid 30470662)
26. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25, 139-149 (2006). (Pubitemid 43077303)
27. Jiang G, Espeseth A, Hazuda DJ, Margolis DM. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodefciency virus type 1 promoter. J. Virol. 81(20), 10914-10923 (2007). (Pubitemid 47536066)
28. Tyagi M, Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J. 26(24), 4985-4995 (2007). (Pubitemid 350261291)
29. Archin NM, Liberty AL, Kashuba AD et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 25, 482-485 (2012).
30. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet 366, 1809-1820 (2005). (Pubitemid 41642647)
31. Slots J. Human viruses in periodontitis. Periodontol 2000 53, 89-110 (2010).
32. Kurita-Ochiai T, Fukushima K, Ochiai K. Volatile fatty acids, metabolic by-products of periodontopathic bacteria, inhibit lymphocyte proliferation and cytokine production. J. Dent. Res. 74, 1367-1373 (1995).
33. Kurita-Ochiai T, Seto S, Suzuki N et al. Butyric acid induces apoptosis in infamed fbroblasts. J. Dent. Res. 87, 51-55 (2008).
34. Niederman R, Buyle-Bodin Y, Lu BY, Robinson P, Naleway C. Short-chain carboxylic acid concentration in human gingival crevicular fuid. J. Dent. Res. 76, 575-579 (1997). (Pubitemid 127732637)
35. Murdoch DA. Gram-positive anaerobic cocci. Clin. Microbiol. Rev. 11, 81-120 (1998). (Pubitemid 28046017)
36. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. The microbiology of butyrate formation in the human colon. FEMS Microbiol. Lett. 217, 133-139 (2002). (Pubitemid 35441298)
37. Belyakov IM, Ahlers JD. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine. Trends Immunol. 29, 574-585 (2008).
38. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 1, 23-30 (2008).
39. Kotler DP. HIV infection and the gastrointestinal tract. AIDS 19, 107-117 (2005). (Pubitemid 40409529)
40. Wilson MJ, Hall V, Brazier J, Lewis MA. Evaluation of a phenotypic scheme for identifcation of the 'butyrate-producing' Peptostreptococcus species. J. Med. Microbiol. 49, 747-751 (2000). (Pubitemid 30623908)
41. Jotwani R, Muthukuru M, Cutler CW Increase in HIV receptors/co-receptors/ a-defensins in infamed human gingiva. J. Dent. Res. 83, 371-377 (2004). (Pubitemid 41766091)
42. Giacaman RA, Nobbs AH, Ross KF, Herzberg MC. Porp hyromonas gingiva lis selectively up-regulates the HIV-1 coreceptor CCR5 in oral keratinocytes. J. Immunol. 179, 2542-2550 (2007).
43. Giacaman RA, Asrani AC, Gebhard KH et al. Porp hyromonas gingivalis induces CCR5-dependent transfer of infectious HIV-1 from oral keratinocytes to permissive cells. Retrovirology 5, 1-14 (2008).
44. Scully C, Porter SR, Mutlu S, Epstein JB, Glover S, Kumar N. Periodontopathic bacteria in English HIV-seropositive persons. AIDS Patient Care STDS 13, 369-374 (1999). (Pubitemid 29282645)
45. Kashanchi F, Melpolder JC, Epstein JS, Sadaie MR. Rapid and sensitive detection of cell-associated HIV-1 in latently infected cell lines and in patient cells using sodium-n-butyrate induction and RT-PCR. J. Med. Virol. 52, 179-189 (1997). (Pubitemid 27239318)
46. Herbein G, Varin A, Larbi A et al. Nef and TNFalpha are coplayers that favor HIV-1 replication in monocytic cells and primary macrophages. Curr. HIV Res. 6, 117-129 (2008). (Pubitemid 351479791)
47. Imai K, Victriano AF, Ochiai K, Okamoto T. Microbial interaction of periodontopathic bacterium Porphyromonas gingivalis and HIV - possible causal link of periodontal diseases to AIDS progression. Curr. HIV Res. 10, 238-244 (2012).
48. Gupta K, Klasse PJ. How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked? PLoS Med. 3, e79 (2006).
49. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365-1371 (2006). (Pubitemid 44924494)
50. Haynes BF. Gut microbes out of control in HIV infection. Nat. Med. 12, 1351-1352 (2006). (Pubitemid 44924488)
51. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat. Immunol. 7, 235-239 (2006).
52. Kornbluth RS, Oh PS, Munis JR, Cleveland PH, Richman DD. Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodefciency virus in vitro. J. Exp. Med. 169, 1137-1151 (1989). (Pubitemid 19085845)
53. Bernstein MS, Tong-Starksen SE, Locksley RM. Activation of human monocyte-derived macrophages with lipopolysaccharide decreases human immunodefciency virus replication in vitro at the level of gene expression. J. Clin. Invest. 88, 540-545 (1991).
54. Verani A, Scarlatti G, Comar M et al. C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells. J. Exp. Med. 185, 805-816 (1997). (Pubitemid 27119864)
55. Sewankambo N, Gray RH, Wawer MJ et al. HIV-1 infection associated with abnormal vaginal fora morphology and bacterial vaginosis. Lancet 350, 546-550 (1997). (Pubitemid 27348430)
56. Spiegel CA, Amsel R, Eschenbach D, Schoenknecht F, Holmes KK. Anaerobic bacteria in nonspecifc vaginitis. N. Engl. J. Med. 303, 601-607 (1980).
57. Taha TE, Gray RH, Kumwenda NI et al. HIV infection and disturbances of vaginal fora during pregnancy. J. Acquir. Immune Defc. Syndr. Hum. Retrovirol. 20, 52-59 (1999). (Pubitemid 29045470)
58. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28, 1221-1227 (1987). (Pubitemid 17156038)
59. Mortensen PB, Clausen MR. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand. J. Gastroenterol. Suppl. 216, 132-148 (1996). (Pubitemid 26129312)
60. Stein TP, Koerner B, Schluter MD et al. Weight loss, the gut and the infammatory response in aids patients. Cytokine 9, 143-147 (1997). (Pubitemid 27116890)